ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Cardiovascular Disease

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

12,651Medicare Part D Prescriptions Filled, Including Refills

Rank: 6 out of 323

$978K Total Retail Price of All Prescriptions

Rank: 2 out of 323

670 Patients Receiving at Least One Drug in Part D
93%Patients 65 Years and Older
6% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Indiana
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

2% of this provider’s 670 patients filled at least one prescription for a schedule three drug, compared to an average of 1%.

Risky Drugs to Seniors

0% of this provider’s 11,825 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 0%.

Brand Name Drugs

37% of this provider’s prescriptions were for brand-name drugs, compared to an average of 24%.

Prescription Price

$77 was the average price of a prescription from this provider, compared to $58 among peers.

Prescriptions per Patient

19 is the average number of prescriptions (including refills) per patient, compared to an average of 11.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Indiana
SIMVASTATIN 858 806 1 4
AMLODIPINE BESYLATE 745 704 2 7
DIOVAN 563 553 3 27
METOPROLOL TARTRATE 535 497 4 3
WARFARIN SODIUM 507 472 5 5
ATORVASTATIN CALCIUM 455 434 6 10
TEKTURNA 426 423 10 7 90
CRESTOR 424 391 8 14
METOPROLOL SUCCINATE 363 329 9 8
FUROSEMIDE 358 345 10 6
LOSARTAN POTASSIUM 355 344 11 17
HYDROCHLOROTHIAZIDE 314 252 12 18
LISINOPRIL 311 286 13 2
ATENOLOL 291 277 14 16
DIGOXIN 236 214 15 15
NIASPAN 209 195 16 38
CLOPIDOGREL 205 187 17 9
POTASSIUM CHLORIDE 198 187 18 20
CARVEDILOL 173 142 19 1
ZETIA 163 153 20 25
RAMIPRIL 153 125 21 23
BENICAR 143 142 22 76
DIOVAN HCT 135 130 23 56
PLAVIX 134 124 24 12
LEVOTHYROXINE SODIUM 128 128 25 28
SPIRONOLACTONE 128 127 25 19
NITROSTAT 113 103 27 21
QUINAPRIL HCL 111 100 28 60
CLONIDINE HCL 104 104 29 41
METFORMIN HCL 97 91 30 54
WELCHOL 91 89 31 95
EXFORGE 89 84 32 103
SERTRALINE HCL 85 84 33 95
TRILIPIX 84 80 34 77
ISOSORBIDE MONONITRATE ER 83 83 35 11
ALLOPURINOL 78 78 36 64
XARELTO 74 62 37 97
SOTALOL 73 70 38 32
LOSARTAN-HYDROCHLOROTHIAZIDE 72 72 39 40
OMEPRAZOLE 71 70 40 31
DILTIAZEM 24HR ER 70 70 41 33
LIPITOR 69 65 42 58
ENALAPRIL MALEATE 68 68 43 29
AMLODIPINE BESYLATE-BENAZEPRIL 68 68 43 65
COUMADIN 68 68 43 35
NITROGLYCERIN PATCH 67 60 46 39
PROPRANOLOL HCL 58 58 47 119
LOVASTATIN 57 57 48 52
TEKTURNA HCT 54 50 49 146
FAMOTIDINE 52 40 50 48
BENAZEPRIL HCL 52 40 50 68
ZOLPIDEM TARTRATE 50 48 52 72
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Jan. 17, 2014.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.